Protein Therapeutics Companies

Biogen acquires Nightstar Therapeutics Biogen, a leading biotechnology company, acquired Nightstar Therapeutics in December 2023. Nightstar specializes in gene therapy treatments for inherited retinal disorders, expanding Biogen's presence in the gene therapy space with promising protein-based solutions.

Amgen launches biosimilar version of Avastin Amgen, a major player in the protein therapeutics market, launched a biosimilar version of Avastin, a blockbuster cancer drug, in January 2024. This move signals Amgen's focus on expanding its biosimilar offerings and making protein-based treatments more accessible.

Regeneron receives approval for Dupixent in eosinophilic esophagitis Regeneron's Dupixent, a monoclonal antibody, received FDA approval for the treatment of eosinophilic esophagitis in December 2023. This expands the reach of protein therapeutics in addressing previously unmet needs in gastrointestinal disorders.

Sanofi and Alnylam announce positive Phase 3 results for patisiran in hereditary ATTR amyloidosis Sanofi and Alnylam announced positive Phase 3 results for patisiran, a siRNA therapy, in treating hereditary ATTR amyloidosis. This marks a significant advancement in the use of protein therapeutics for rare genetic diseases.

• Abbott Laboratories (US)


• Amgen Inc. (US)


• Baxter International Inc. (US)


• Eli Lilly and Company (US)


• F. Hoffmann-La Roche Ltd. (Switzerland)


• Johnson & Johnson (US)


• Merck & Co. Inc. (US)


• Novo Nordisk A/S (Denmark)


• CSL Behring (US)


• Bristol Myers Squibb Co. (US)


• Pfizer Inc (US)


• Sanofi (France)